Azelnidipine Demonstrates Efficacy in Lowering BP in Indian Patients with Hypertension: Study
Hypertension (HTN) is a prevalent cardiovascular condition with significant morbidity and mortality worldwide. Azelnidipine, a selective calcium channel blocker, has shown promise in lowering blood pressure (BP) in hypertensive patients. Azelnidipine is known for its potent antihypertensive effects and has been widely used in the management of mild to moderate hypertension. However, its effectiveness in Indian patients has not been extensively studied.
A recent retrospective real-world evidence (RWE) study conducted in Indian patients aimed to evaluate the efficacy of azelnidipine in this population.This study was published in the Journal Of Association Of Physicians Of India by Chetan Shah and colleagues. The retrospective cohort study included 882 Indian patients aged 18 years or older with mild to moderate hypertension who had been on azelnidipine treatment for the last 3 months.
Data were collected on changes in systolic and diastolic BP from baseline to subsequent visits (4 and 12 weeks), as well as the proportion of patients achieving target BP levels.The key findings of the study were:
Mean reduction in systolic/diastolic BP from baseline to 12 weeks: 13.92/7.91 mm Hg (p < 0.0001)
Mean reduction in systolic/diastolic BP in newly diagnosed HTN patients: 11.77/7.43 mm Hg (p < 0.0001)
Mean reduction in systolic/diastolic BP in known cases of HTN: 16.50/8.48 mm Hg (p < 0.0001)
Mean reduction in systolic/diastolic BP in diabetic patients: 15.35/8.69 mm Hg (p < 0.0001)
Proportion of patients achieving target BP of <130/80 mm Hg: 4.99%
Proportion of patients achieving target BP of <140/90 mm Hg: 46.26%
Mean change in heart rate (HR) from baseline: reduction of 5.22 beats/minute
The study findings suggest that azelnidipine is effective in lowering BP and HR in Indian patients with mild to moderate hypertension. With significant reductions observed in BP and HR, azelnidipine demonstrates potential as an effective antihypertensive drug in this population. These results highlight the importance of considering azelnidipine as a treatment option for hypertension management in Indian patients.
Reference:
